Back

Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression

chen, m.; tu, c.; Tan, C.; Zheng, X.; wang, x.; wu, j.; Huang, Y.; wang, z.; yan, y.; li, z.; shan, h.; Liu, J.; huang, j.

2020-04-11 respiratory medicine
10.1101/2020.04.06.20054890
Show abstract

BackgroundCOVID-19 is a new and highly contagious respiratory disease that has caused global spread, high case fatality rate in severe patients, and a huge medical burden due to invasive mechanical ventilation. The current diagnosis and treatment guidelines are still need to be improved, and more excellent clinical experience is needed to provide reference. MethodsWe analyzed and summarized clinical data of 97 confirmed COVID-19 adult patients (including 26 severe cases) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 17, 2020 to March 10, 2020, included laboratory examination results, imaging findings, treatment effect, prognosis, etc, in order to put forward prediction index of severe COVID-19 patients, principles of early intervention and methylprednisolone usages in COVID-19 patients. ResultsO_LIHypoxemia, hyperlactic acid, hypoproteinemia, and hypokalemia were prevalent in COVID-19 patients. The significant low lymphocyte count, hypoproteinemia, hypokalemia, the persistent or worsen high CRP, high D-dimer, and high BNP, and the occurrence of hemoptysis and novel coronavirus (SARS-CoV-2) viremia were important indicators for early diagnosis and prediction of severe disease progression. C_LIO_LICharacteristic images of lung CT had a clear change in COVID-19, Ground-glass opacity (GGO) and high-density linear combinations may indicate different pathological changes. Rapid lobular progression of GGO suggests the possibility of severe disease. C_LIO_LIBasic principles of early intervention treatment of COVID-19: on the premise of no effective antiviral drugs, treatment is based on supportive and symptomatic therapy (albumin supplementation, supplement of potassium, supplement blood plasma, etc.) in order to maintain the stability of the intracellular environment and adequately reactivate body immunity to clean up SARS-CoV-2. C_LIO_LIAccording to severity, oxygenation index, body weight, age, underlying diseases, appropriate amount methylprednisolone application on severe/critical COVID-19 patients on demand, improved blood oxygen and reduced the utilization rate of invasive mechanical ventilation, case fatality rate and medical burden significantly. The most common indications for invasive mechanical ventilation should be strictly control in critical COVID-19 patients. C_LI ConclusionsO_LIAccurate and timely identification of clinical features in severe risks, and early and appropriate intervention can block disease progression. 2. Appropriate dose of methylprednisolone can effectively avoid invasive mechanical ventilation and reduce case fatality rate in critical COVID-19 patients. C_LI

Matching journals

1
Medicine
Ovid Technologies (Wolters Kluwer Health) · based on 29 published papers
Top 0.1%
51× avg
2
Annals of Translational Medicine
AME Publishing Company · based on 14 published papers
#1
89× avg
3
Frontiers in Medicine
Frontiers Media SA · based on 99 published papers
Top 0.9%
12× avg
4
PLOS ONE
Public Library of Science (PLoS) · based on 1737 published papers
Top 61%
6.6%
5
Respiratory Research
Springer Science and Business Media LLC · based on 10 published papers
Top 0.4%
82× avg
6
European Respiratory Journal
European Respiratory Society (ERS) · based on 44 published papers
Top 1%
15× avg
7
Signal Transduction and Targeted Therapy
Springer Science and Business Media LLC · based on 10 published papers
#1
119× avg
8
Scientific Reports
Springer Science and Business Media LLC · based on 701 published papers
Top 48%
3.1%
9
BMJ Open Respiratory Research
BMJ · based on 32 published papers
Top 0.9%
18× avg
10
Journal of Medical Virology
Wiley · based on 95 published papers
Top 4%
6.7× avg
11
Clinical and Translational Medicine
Wiley · based on 11 published papers
Top 0.3%
40× avg
12
Frontiers in Pharmacology
Frontiers Media SA · based on 27 published papers
Top 2%
10× avg
13
BMJ Open
BMJ · based on 553 published papers
Top 44%
1.4%
14
ERJ Open Research
European Respiratory Society (ERS) · based on 36 published papers
Top 2%
7.4× avg
15
EMBO Molecular Medicine
Springer Science and Business Media LLC · based on 15 published papers
Top 1.0%
14× avg
16
Frontiers in Molecular Biosciences
Frontiers Media SA · based on 10 published papers
Top 0.4%
27× avg
17
Journal of Clinical Medicine
MDPI AG · based on 77 published papers
Top 13%
2.1× avg
18
Frontiers in Immunology
Frontiers Media SA · based on 140 published papers
Top 7%
2.5× avg
19
Epidemiology and Infection
Cambridge University Press (CUP) · based on 80 published papers
Top 10%
2.5× avg
20
Aging
Impact Journals, LLC · based on 18 published papers
Top 4%
5.7× avg
21
Frontiers in Cellular and Infection Microbiology
Frontiers Media SA · based on 22 published papers
Top 3%
5.6× avg
22
JMIR Public Health and Surveillance
JMIR Publications Inc. · based on 45 published papers
Top 10%
2.4× avg
23
Journal of Allergy and Clinical Immunology
Elsevier BV · based on 15 published papers
Top 2%
9.1× avg
24
BMC Public Health
Springer Science and Business Media LLC · based on 148 published papers
Top 21%
0.8%
25
Journal of Translational Medicine
Springer Science and Business Media LLC · based on 21 published papers
Top 1%
7.5× avg
26
Frontiers in Pediatrics
Frontiers Media SA · based on 24 published papers
Top 3%
6.3× avg
27
Clinical Infectious Diseases
Oxford University Press (OUP) · based on 219 published papers
Top 19%
0.8%
28
Critical Care
Springer Science and Business Media LLC · based on 14 published papers
Top 2%
7.3× avg
29
International Journal of Infectious Diseases
Elsevier BV · based on 115 published papers
Top 19%
0.7%
30
Vaccines
MDPI AG · based on 131 published papers
Top 7%
2.2× avg